Pacira Pharmaceuticals Inc. (PCRX) Tops Q2 EPS by 7c; Reaffirms Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts PCRX Hot Sheet
Join SI Premium – FREE
Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) reported Q2 EPS of ($0.51), $0.07 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $3.6 million versus the consensus estimate of $3.5 million.
Reaffirms outlook.
Reaffirms outlook.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Verra Mobility (VRRM) Tops Q3 EPS by 10c ; Offers Guidance
- Cboe Global Markets (CBOE) Tops Q3 EPS by 21c
- Oxford Square Capital Corp. (OXSQ) Misses Q3 EPS by 1c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
